FAAH Gene Expression Altered in Chronic Migraine Patients, Linked to Psychiatric Symptoms

FAAH (fatty acid amide hydrolase), the enzyme that breaks down the endocannabinoid anandamide, showed significantly lower gene expression in medication overuse headache (MOH) patients compared to episodic migraine (EM) patients. Paradoxically, FAAH protein levels were higher in MOH patients. Lower FAAH gene expression correlated with worse headache impact scores (HIT-6), disability scores (MIDAS), and higher scores on anxiety, depression, and alexithymia scales.

Cross-sectional study of 31 patients (15 episodic migraine, 16 medication overuse headache) and 14 healthy controls. FAAH was measured via ELISA (protein) and real-time quantitative PCR (gene expression) in peripheral blood mononuclear cells. Seven additional ECS components were also assessed. Clinical and psychopathological scales administered.

The endocannabinoid system is a key regulator of pain, and FAAH is the enzyme that determines how long endocannabinoids remain active. Finding that FAAH is specifically altered in chronic migraine patients suggests the endocannabinoid system may be dysregulated in headache chronification, potentially explaining why some migraine patients report benefit from cannabis.

FAAH inhibitors have been explored as potential therapeutics for pain and anxiety. This study suggests FAAH dysregulation may be a biomarker that distinguishes chronic migraine from episodic migraine, potentially opening a path toward endocannabinoid-based treatments for headache disorders.

Very small sample size (31 patients, 14 controls). Cross-sectional design; cannot determine if FAAH changes cause or result from chronic migraine. Peripheral blood measurements may not reflect brain endocannabinoid levels. No cannabinoid receptor gene expression differences found between groups.